• Explore /
  • Poster
  • / POF (paclitaxel/oxaliplatin/5-FU/leucovorin) versus SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial.

POF (paclitaxel/oxaliplatin/5-FU/leucovorin) versus SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial.

Abstract Poster

Authors

null

Liyu Su

Gastrointestinal Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China

Liyu Su , Chunxiang Li , Feng Huang , Lu chuan Chen , Lisheng Cai , Jiayi Li , Shen Zhao , Rongbo Lin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03788226

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4647)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4647

Abstract #

TPS4647

Poster Bd #

255

Abstract Disclosures

Similar Posters

First Author: Suganija Lakkunarajah

First Author: In Gyu Hwang

First Author: Manish A. Shah

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

First Author: Hiroyuki Arai